What guidance did Crinetics's management provide for the next earnings period?

What does Crinetics do and what are its main business segments?

What is the market's earnings forecast for Crinetics next quarter?

What were the key takeaways from Crinetics’s earnings call?

What is Crinetics's gross profit margin?

What factors drove the changes in Crinetics's revenue and profit?

What were the key takeaways from Crinetics's earnings call?

Did Crinetics beat or miss consensus estimates last quarter?

- **Breakout Year Achievements**: PALSONIFY launched with 200+ Q4 enrollments, 50% commercial reimbursement, and top payer formulary wins.
- **Pipeline Momentum**: Atumelnant Phase II/III ADCS study starts in H1 2026; CRN09682 enters Phase I/II for SST2-expressing tumors.
- **Financial Strength**: $1.4 billion cash post-January 2026 offering; 2026 operating expenses guided at $600-650 million.
- **Innovative Study Design**: ADCS trial features adaptive dosing and proactive glucocorticoid replacement to address historical Cushing's treatment challenges, PALSONIFY's rapid onset and symptom control drive prescriber confidence.

**【CEO Summary Section】**
- 2025 was a transformative year with the successful U.S. launch of PALSONIFY for acromegaly, achieving 200+ enrollment forms in Q4 and securing top payer formulary wins.
- Phase II data for atumelnant in CAH and Cushing's disease (ADCS) showed rapid cortisol lowering, with a seamless Phase II/III study for ADCS expected to start in H1 2026.
- CRN09682, a novel non-peptide drug conjugate, entered Phase I/II testing in SST2-expressing tumors, targeting neuroendocrine and other cancers.
- The company ended 2025 with $1 billion in cash, enabling a 5-year runway for pipeline advancement and commercialization.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $6.2 million (including $5.4 million from PALSONIFY and $0.8 million from SKK licensing).
- Full-year 2025 operating expenses: $326.2 million, below guidance due to working capital timing.
- 2026 guidance: GAAP operating expenses $600-650 million, driven by clinical trials and commercialization.
- Post-January 2026 public offering, cash balance reached $1.4 billion.

**【Q&A Highlights】**
- **PALSONIFY Launch**: 50% of patients reimbursed commercially, 50% on Quickstart program; prescribers highlight fast onset and symptom control.
- **ADCS Study Design**: Phase II/III study will test 20-80 mg doses, with a proactive glucocorticoid replacement paradigm; primary endpoint: urine-free cortisol normalization.
- **CRN09682 Trial**: Dose escalation underway in SST2-expressing tumors; safety and tumor response data expected in 2026.
- **Competitive Position**: PALSONIFY's efficacy-first messaging resonates with prescribers, with no significant payer pushback reported.


Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

- **Strong PALSONIFY launch**: 95% of top prescribers contacted, 50% of prescriptions reimbursed early, with Q4 2025 metrics expected. 
- **Financial stability**: $1.1B cash, sufficient runway to 2029, despite Q3 R&D/S&G expenses up 13% and 5%. 
- **Pipeline progress**: Phase 3 trials for Atumelnant (CAH) and paltusotine (carcinoid) starting in Q4 2025; CRN09682 Phase 1/2 trial underway. 
- **Key risks**: Graves' disease and ADPKD programs delayed; no rebate agreements for PALSONIFY. 
- **Growth drivers**: Community prescriber adoption (70% of scripts), Quick Start program, and 12-month payer approvals. 


**【CEO Summary Section】**
- Launched PALSONIFY for acromegaly, with 95% of top prescribers contacted and 50% of prescriptions reimbursed early in the launch. 
- Phase 1 strategy focuses on switching patients from injectables, with 95% of initial prescriptions from switch patients. 
- Positive feedback from community endocrinologists and payers, with prior authorizations approved in days. 
- Q4 2025 will provide first full-quarter metrics, including revenue, new patient starts, and prescriber count. 
- Pipeline updates: Graves' disease candidate delayed due to tox signals; SST3 agonist for ADPKD also delayed. 
- Phase 3 trials for Atumelnant in CAH and paltusotine in carcinoid syndrome progressing, with first patients randomized in Q4 2025. 

**【CFO Financial Commentary】**
- Q3 2025 revenue: $0.1M from Japan licensing deal; no PALSONIFY revenue due to late Q3 approval. 
- R&D expenses: $90.5M (vs. $80.3M prior quarter), driven by clinical trial start-up costs. 
- SG&A expenses: $52.3M (vs. $49.8M prior quarter), reflecting launch investments. 
- Cash position: $1.1B, with guidance for $340-370M net cash use in 2025. 
- Sufficient runway to fund operations into 2029. 

**【Q&A Highlights】**
- **Payer dynamics**: 50% of claims reimbursed, with approvals for up to 12-month supplies. No rebate agreements planned. 
- **Graves' disease candidate**: Delayed IND timelines due to tox signals; backup molecules prioritized. 
- **Atumelnant in CAH**: Cohort 4 data expected in Q1 2026, with focus on glucocorticoid tapering and adrenal androgen suppression. 
- **Commercial strategy**: Focus on community prescribers (70% of prescriptions) and PTC centers (30%), with Quick Start program supporting early access. 
- **Pipeline momentum**: BRAVESST2 Phase 1/2 trial for CRN09682 in SST2-expressing tumors underway, with first patients dosed. 


Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

- **Paltusotine Approval Imminent**: FDA review on track for September 2025, with U.S. launch preparations finalized.
- **Pipeline Momentum**: Atumelnant Phase II/III in Cushing's (H1 2026), TSH antagonist IND submissions in 2025, and CRN09682 entering Phase I/II.
- **Financial Strength**: $1.2 billion cash runway supports 2029 operations; Q2 R&D/SG&A up 5.4%/40.3% to accelerate clinical and commercial readiness.
- **Strategic Focus**: Targeting 11,000 diagnosed acromegaly patients with PALSONIFY, leveraging faster IGF-1 control and convenience over injectables.
- **Innovation in Endocrinology**: TSH antagonist for Graves' disease and SST3 agonist for solid tumors highlight Crinetics' novel mechanism-first approach.

**【CEO Summary Section】**
- **Paltusotine NDA Update**: On track for FDA approval in September 2025, with strong engagement from the FDA. The launch team is prepared for a U.S. commercial debut, supported by 30 sales representatives and comprehensive patient engagement initiatives.
- **Pipeline Progress**: 
  - Paltusotine for carcinoid syndrome and atumelnant for CAH are advancing clinical trials. Atumelnant's Phase II/III study in Cushing's syndrome is expected to initiate in H1 2026.
  - CRN12755, a TSH receptor antagonist for Graves' disease, shows potential as a novel oral therapy targeting disease root causes.
- **Commercial Strategy**: Focus on untreated and treatment-switching acromegaly patients (11,000 diagnosed, 500 newly diagnosed annually). Patient activation campaigns aim to drive demand for PALSONIFY, which offers faster IGF-1 control and convenience over injectables.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: 
  - Revenue: $1 million from SKK licensing.
  - R&D Expenses: $80.3 million (up 5.4% QoQ) due to clinical trial expansion.
  - SG&A: $49.8 million (up 40.3% QoQ) for commercial readiness.
  - Cash Position: $1.2 billion, sufficient for operations into 2029.
- **Guidance Update**: Net cash used in 2025 revised to $340-370 million (from $340-380 million), reflecting optimized clinical timelines and cost management.

**【Q&A Highlights】**
- **Launch Dynamics**: PALSONIFY adoption expected to ramp gradually due to infrequent endocrinologist visits (2-4x/year). Formulary placement may take 6-9 months post-approval.
- **Pricing Strategy**: No pre-approval comments on price, but payers recognize PALSONIFY's value in reducing treatment burden (e.g., 13+ annual injections for SRLs).
- **Atumelnant Safety**: Liver function elevation in Phase II observed in 1 patient; ongoing data collection shows no emerging safety signals.
- **Competitive Landscape**: CRENESSITY launch highlights CAH unmet need, but Crinetics' broader atumelnant patient population (A4 and GC reduction) differentiates from competitors.
- **Graves' Disease Innovation**: TSH receptor antagonist CRN12755 aims to address both hyperthyroidism and thyroid eye disease with a single oral therapy, avoiding risks of anti-thyroid drugs.


Crinetics Pharmaceuticals (CRNX)-7 Aug 25-2025 Q2 Earnings call transcript

- **Paltusotine NDA Milestone**: FDA acceptance for acromegaly with PDUFA date in September 2025; European MAA filing planned for H1 2025.
- **Commercial Readiness**: 100% MSL outreach to academic targets, payer partnerships, and patient support infrastructure for launch.
- **Atumelnant Phase III Innovation**: Proposed endpoint targets glucocorticoid dose reduction and adrenal androgen normalization, reflecting unique mechanism.
- **Pipeline Expansion**: 4 late-stage programs advancing in 2025, with $340-380M cash burn supported by $1.4B cash balance.
- **Leadership Transition**: Marc Wilson exits after 7 years; Tobin Schilke to lead as CFO during critical launch phase.

**【CEO Summary Section】**
- Crinetics achieved a transformative 2024 with key milestones: FDA NDA acceptance for paltusotine in acromegaly (PDUFA date: September 25, 2025), expansion of European infrastructure, and Phase II/III clinical progress across multiple programs.
- Paltusotine's commercial readiness is supported by a 100% MSL outreach to academic targets, strategic partnerships with payers, and a comprehensive patient support center.
- Atumelnant Phase II data in CAH showed rapid normalization of A4 and 17-OHP, with plans for Phase III trials in adults and children, targeting broader inclusion criteria.
- The pipeline includes 4 late-stage programs (paltusotine, atumelnant, CRN09682, and PTH antagonist) and 10 wholly owned assets, with IND submissions for 4 new programs in 2025.

**【CFO Financial Commentary】**
- 2024 net loss: $298.4 million (vs. $214.5 million in 2023), driven by R&D ($240.2M) and G&A ($99.7M) growth for pipeline expansion and commercial readiness.
- 2025 cash burn projected at $340-380 million, funded by $1.4 billion in cash, supporting 4 late-stage trials and launch preparations.
- CFO Marc Wilson transitions out after 7 years, succeeded by Tobin Schilke, with no immediate financial impact anticipated.

**【Q&A Key Highlights】**
- **Paltusotine Launch Strategy**: U.S. and Europe parallel launches, with European MAA filing in H1 2025. Payers emphasize paltusotine's rapid onset, sustained efficacy, and once-daily convenience over generics.
- **Atumelnant Phase III Design**: Proposed endpoint captures glucocorticoid dose reduction and adrenal androgen normalization, reflecting atumelnant's unique MC2R mechanism.
- **Pipeline Prioritization**: All 4 late-stage programs (paltusotine, atumelnant, CRN09682, PTH antagonist) advance in parallel, with CRN09682 IND submission in early 2025.
- **Risks & Contingencies**: Regulatory delays (FDA mid-cycle review pending), clinical trial enrollment competition (CAH), and generic market dynamics (e.g., Cipla in acromegaly).

Actual								-0.71	-0.53	-0.56	-0.66	-0.69	-0.7	-0.73	-0.68	-0.73	-0.81	-0.78	-0.84	-0.85	-0.94	-1.01	-0.9	-0.93	-0.94	-0.96	-0.88	-1.04	-1.23	-1.38	-1.29
Forecast								-0.63	-0.5533	-0.526	-0.578	-0.66	-0.6104	-0.716	-0.625	-0.58	-0.6414	-0.7846	-0.8229	-0.8252	-0.8656	-0.867	-0.8625	-0.8096	-0.8589	-0.9107	-0.8861	-0.9408	-1.0815	-1.2444	-1.348
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12.70%	+4.21%	-6.46%	-14.19%	-4.55%	-14.68%	-1.96%	-8.80%	-25.86%	-26.29%	+0.59%	-2.08%	-3.01%	-8.60%	-16.49%	-4.35%	-14.87%	-9.44%	-5.41%	+0.69%	-10.54%	-13.73%	-10.90%	+4.30%

Actual	--	--	--	--	--	--	--	71.00K	0	0	0	0	0	0	1.08M	3.13M	439.00K	458.00K	709.00K	2.68M	988.00K	346.00K	0	640.00K	399.00K	0	0	361.00K	1.03M	143.00K	6.16M
Forecast	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	5.20M	600.00K	250.00K	250.00K	254.25K	1.10M	0	197.10K	200.00K	467.27K	218.09K	723.73K	137.50K	613.73K	429.85K	4.49M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-39.79%	-26.83%	+83.20%	+183.60%	+953.69%	-9.94%	0.00%	-100.00%	+220.00%	-14.61%	-100.00%	-100.00%	+162.55%	+67.99%	-66.73%	+37.22%

CRNX

CRNX fundamentals

CRNX Q4 2025 Earnings

Earnings Call

You can ask Aime

CRNX

CRNX fundamentals

CRNX Q4 2025 Earnings

Earnings Call

CRNX Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

CRNX Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

CRNX Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

CRNX Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

CRNX Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime